Foghorn Therapeutics Inc. at Goldman Sachs Healthcare Conference Transcript
Okay. Thank you, everyone, for joining us. We'll continue with the next session. I'm Paul Choi, and I cover the small and mid-cap biotechnology sector here at Goldman Sachs. It's my pleasure to welcome, Adrian Gottschalk, to my left, and who is CEO of Foghorn.
What we'll do is continue with the usual format and I'll let Adrian maybe kick it off with some opening remarks and then we'll get to the Q&A. If anybody in the audience has questions, please feel free to raise your hand and we'll get a mic to you. Also, for those people who are listening in on the webcast, if you have any questions, please feel free to e-mail them and I'll read them anonymously.
And with that, I'll turn it over to Adrian.
Great. Good morning, and thanks, Paul. Thanks for having us here at the conference. Just hoping for a little bit more sun in Southern California.
Yes, we all are.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
